| ²é¿´: 573 | »Ø¸´: 2 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
yin198716гæ (ÕýʽдÊÖ)
|
[ÇóÖú]
·ÒëÇóÖú
|
|
| What about the ways of DLL4 targeting? As mentioned above, one of them is specific targeting using anti-DLL4 antibodies. Unlike ¦Ã-secretase inhibitors, anti-DLL4 antibodies did not induce gastrointestinal toxicity. They have no discernible impact on goblet cell differentiation or crypt progenitor cell proliferation. Hoey et al. found that selective antihuman antibody 21M18 inhibited expression of Notch target genes including HES1 and ATOH1, which in effect caused a low level of malignant cell proliferation . |
» ²ÂÄãϲ»¶
²ÄÁÏר˶322
ÒѾÓÐ7È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ20È˻ظ´
Ò»Ö¾Ô¸Ö£ÖÝ´óѧ085600Çóµ÷¼Á
ÒѾÓÐ20È˻ظ´
»¯Ñ§µ÷¼Á
ÒѾÓÐ17È˻ظ´
3-äåßÁà¤-4-¼×È©ºÏ³É
ÒѾÓÐ9È˻ظ´
Ò»Ö¾Ô¸ÄϾ©º½¿Õº½Ìì´óѧ ²ÄÁÏÓ뻯¹¤329·ÖÇóµ÷¼Á
ÒѾÓÐ3È˻ظ´
285Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
²ÄÁÏÇóµ÷¼Á
ÒѾÓÐ11È˻ظ´
µ÷¼Á
ÒѾÓÐ8È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ14È˻ظ´

RXMCDM
°æÖ÷ (ÎÄ̳¾«Ó¢)
- ·ÒëEPI: 530
- Ó¦Öú: 401 (˶ʿ)
- ¹ó±ö: 1.908
- ½ð±Ò: 38947.6
- É¢½ð: 4908
- ºì»¨: 88
- ɳ·¢: 4
- Ìû×Ó: 11453
- ÔÚÏß: 1355.6Сʱ
- ³æºÅ: 2739168
- ×¢²á: 2013-10-20
- ÐÔ±ð: GG
- רҵ: Ò»°ã¹ÜÀíÀíÂÛÓëÑо¿·½·¨ÂÛ
- ¹ÜϽ: ÂÛÎÄ·Òë
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï
yin198716: ½ð±Ò+5, ·ÒëEPI+1 2014-02-24 15:34:00
yin198716: ½ð±Ò+5, ·ÒëEPI+1 2014-02-24 15:34:00
|
DLL4°ÐÏò·½Ê½ÊÇÔõôÑùµÄ£¿ÈçÉÏËùÊö£¬ÆäÖÐÖ®Ò»ÊÇÌØ¶¨µÄ¿¹DLL4¿¹Ìå°ÐÏò¡£Óë¦Ã-·ÖÃÚøÒÖÖÆÒò×Ó²»Í¬£¬¿¹DLL4¿¹Ìå²»ÓÕµ¼Î¸³¦µÀ¶¾ÐÔ¡£ËûÃǶԱ״ϸ°û·Ö»¯»òÒþÎÑ×æÏ¸°ûµÄÔöֳûÓÐÃ÷ÏÔµÄÓ°Ïì¡£HoeyµÈ·¢ÏÖ¿¹ÈË¿¹Ìå21M18Ñ¡ÔñÐÔÒÖÖÆ°üÀ¨HES1»ùÒòºÍATOH1»ùÒòÔÚÄÚµÄNotch°Ð»ùÒò£¬ÒÖÖÆ°Ð»ùÒòʵ¼ÊÉÏÔì³ÉÁ˶ñÐÔϸ°ûÔöֳˮƽµÍÏ¡£ ¹©²Î¿¼£¡ |

2Â¥2014-02-22 01:18:42
ÓÀÔ¶µÄNO.1
½û³æ (ÎÄ̳¾«Ó¢)
|
±¾ÌûÄÚÈݱ»ÆÁ±Î |
3Â¥2014-02-23 16:01:53














»Ø¸´´ËÂ¥
10